UPDATE: Japan pins international competitiveness hopes on early practical application plan for 'pioneering' drugs and devices
This article was originally published in SRA
Japan has announced ambitious new plans to speed up the development and evaluation of locally developed innovative pharmaceuticals, medical devices and regenerative medicines1. The plans involve prioritized review at the Pharmaceuticals and Medical Devices Agency with a reduction in the overall review period for such products from one year to six months.
You may also be interested in...
The UK’s deployment of COVID-19 vaccines has left vaccine manufacturers worried about emerging discussions on dosing strategies that may not be supported by authorized labeling or published clinical data.
Existing importers and manufacturers of certain medical devices can continue marketing their products for six months or until the Indian medtech regulator makes a final decision on their pending licensing applications.
Differences between how Australia and the EU define “central circulatory system” has resulted in different risk classification levels being assigned to some devices in the two jurisdictions.